METHOD OF TREATMENT OF PATIENTS WITH PROSTATE BENIGNITY HYPERPLASIA, PHARMACEUTICAL PREPARATION CONTAINING INHIBITOR OF 5-ALPHA-REDUCTASE Russian patent published in 1999 - IPC

FIELD: medicine, biochemistry, steroid drugs. SUBSTANCE: method involves administration to patients about 5 mg inhibitor of 5α-reductase in combination with 1-10 mg per a day blocking agent of α₁-adrenoreceptors. Pharmaceutical composition for patients treatment with prostate benignity hyperplasia has 2.5-5.0 mg inhibitor of 5α-reductase and 0.5-10 mg blocking agent of α₁-adrenoreceptors in pharmaceutically acceptable carrier. Inhibitors of 5α-reductase are taken from 17β-substituted 4-azasteroid, 17β-substituted nonazasteroids, 17β-acyl-3-carboxyandrost- -3,5-dienes, derivatives of benzoylaminophenoxybutanoic acid, condensed benz(thio)amides, cinnamoylamides, aromatic 1,2-diesters or thioesters, aromatic ortho-acylaminophenoxy- -alkanoic acids, ortho-thioalkylacylaminophenoxyalkanoic acids or their pharmaceutically acceptable salts and esters. Combined use of two active components provides an enhanced therapeutic effect. EFFECT: enhanced effectiveness of treatment. 15 cl, 101 ex